SVB Leerink analyst Joseph Schwartz maintains Pharvaris (NASDAQ:PHVS) with a Outperform and lowers the price target from $20 to $18.
Monaghan Medical And Premier Inc. Sign 3-Year Agreement To Provide Respiratory Devices To Clinicians, Effective May 1, 2023
Monaghan Medical Corporation (Monaghan) and Premier, Inc., today announced their agreement to a three-year contract, effective May 1, 2023, creating a partnership between two healthcare industry leaders. Under the terms
